M&A · Healthcare · Buyer's industry: Biological Products, (No Diagnostic Substances)
Quince Therapeutics, Inc. to acquire Orphai Therapeutics Inc.
Announced May 18, 2026 · Closed May 18, 2026 · Private target
Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll stock
Transaction
- Acquirer
- Quince Therapeutics, Inc. (QNCX)
- Target
- Orphai Therapeutics Inc.
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed May 18, 2026
Deal protections
Not disclosed for private-company acquisitions.
Advisors
- To the acquirer
- LifeSci Capital
- To the target
- Not disclosed
Classification
- Sector
- Healthcare
- Buyer's industry
- Biological Products, (No Diagnostic Substances)